title: New anticoagulant drugs among elderly patients is caution necessary?: Comment on "The use of dabigatran in elderly patients".
authors.affiliation: Department of Geriatrics and Rehabilitation, Hadassah Hebrew-University Medical Center, Mt Scopus, PO Box 24035, Jerusalem 91240, Israel. jacobsj@hadassah.org.il
authors.forename: Jeremy M
authors.initials: JM
authors.lastname: Jacobs
authors.forename: Jochanan
authors.initials: J
authors.lastname: Stessman
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects / Q000493:pharmacokinetics; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D000069604:Dabigatran; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D019934:International Normalized Ratio; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics*; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D011725:Pyridines; D000069604:Dabigatran